Research Links Shingles Vaccine to Reduced Dementia Risk and Slower Aging
Recent studies have highlighted potential additional benefits of the shingles vaccine beyond its primary purpose of preventing shingles. Research published in the Journals of Gerontology suggests that individuals who received the shingles vaccine exhibited slower biological aging compared to those who did not. Furthermore, emerging research indicates a possible protective effect against dementia. The studies, while showing correlation rather than causation, suggest that the vaccine may help control aging at a molecular level by reducing inflammation, a key factor in aging and disease development. The current shingles vaccine, Shingrix, is noted to be more effective than its predecessor, Zostavax, which was discontinued in the U.S. in 2020. 
